Holland & Knight advised Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey, mobile and modular cleanrooms and biocontainment facilities, on its acquisition by EW Healthcare Partners. The deal was announced on October 18.
Based in Ormond Beach, Florida, Germfree provides advanced solutions for healthcare and life science clients. Its products are well-suited to service major, highly regulated market segments in biopharma, compounding pharmacy and biocontainment. With more than 200 facility installations in 32 countries, Germfree is a global company, committed to enabling its clients to develop new life-saving cures or prevent the next pandemic.
With more than $4 billion raised since inception, EW Healthcare Partners is one of the largest and oldest private healthcare investment firms and seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics and technology-enabled services sectors in the U.S. and in Europe.
Holland & Knight Partners Ivan Colao and Christopher Commander and Associates Elliott Beale and Eliona Jankulla led the firm's representation of Germfree in the deal. They were assisted by Partners Kerry Kehoe, Lawrence Kemm, Ariadna Alvarez, Maria Currier, Elizabeth Burkhard, Marc Druckman, William deMeza and John Dierking, and Associates Patrick Burri and Nathaniel Gardner.
Holland & Knight's corporate practice is ranked as a national first-tier firm in Leveraged Buyouts and Private Equity Law, Corporate Law and M&A Law in the 2022 U.S. News – Best Lawyers "Best Law Firms" guide. The firm is consistently ranked among the Top 25 law firms in the nation advising on U.S. M&A transactions by deal count in Refinitiv and other league tables. Through the HK Deal Flow® program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.
Original source can be found here.